ArticleActa neurologica Belgica2026
Shorter Leukocyte telomere length as a marker of biological aging in relapsing-remitting multiple sclerosis.
Article in Acta neurologica Belgica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundMultiple sclerosis (MS) is increasingly recognized not only as an immune-mediated demyelinating disease but also as a disorder characterized by accelerated biological aging. Leukocyte telomere length (LTL) serves as a hallmark biomarker of cellular senescence, yet its predictive role in early-stage MS and its modulation by shelterin complex genetics remain to be fully elucidated.
methodsIn this cross-sectional study, relative LTL was measured via quantitative polymerase chain reaction in a highly characterized, young cohort of patients with relapsing-remitting MS (RRMS; n = 40, age ≤ 40) and age- and sex-matched healthy controls (n = 39). High-resolution melting analysis was utilized to genotype key shelterin complex polymorphisms: TERF1 (rs10107605, rs1545827) and TERF2 (rs251796). Comprehensive genetic association testing across codominant, dominant, recessive, overdominant, and additive models was conducted alongside clinical/imaging phenotype correlations.
resultsLTL was significantly shorter in RRMS patients than in healthy controls (p = 0.005), suggesting evidence of accelerated biological aging even in this relatively young cohort. Receiver operating characteristic analysis demonstrated modest discriminatory performance area under the curve = 0.698 (95% CI: 0.60-0.79). Notably, across all inheritance models, TERF1 and TERF2 polymorphisms exhibited no significant association with LTL. Furthermore, subgroup analyses revealed that LTL attrition was independent of chronological age, sex, smoking status, or disease duration, indicating that telomere erosion is driven primarily by intrinsic disease-related systemic stress rather than host shelterin genetic predisposition.
conclusionsOur findings demonstrate that leukocyte telomere shortening represents a distinct molecular signature of premature biological aging in young MS patients. By decoupling telomere depletion from primary shelterin genetic variability, this work consistent with disease-driven immunosenescence in MS. In long-standing, heterogeneous disorders like MS, LTL emerges as a promising biomarker for capturing biological decline prior to irreversible neurodegeneration. This study provides a basis for future longitudinal multi-omics investigations exploring telomere dynamics in chronic neuroinflammation.
Indexed as
Identifiers
42837039What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.